IRVINE, Calif., Oct. 17, 2005 (PRIMEZONE) -- "Recent reports splashed across mainstream media indicating that researchers have obtained human embryonic stem cells without aggravating current ethical issues may create a compromise that paves the way for previously prohibited federal funding," stated SmallCap Sentinel analyst D.R. Clark. "If ethical and moral issues that have hampered aspects of stem cell research are cast aside and funding is available to previously forbidden research, one would think this greatly brightens the future for stem cell science."
"An announcement last month that researchers have restored lost motor function to a mouse with spinal cord injuries using human stem cells, has fueled the hopes and dreams of investors and patients," stated Clark. "One can only wonder what the possibilities are for stem cells should research no longer be controversial or otherwise obstructed. If this new stem cell method, which attempts to obtain the cells without destroying embryos is viable, it appears that many moral complaints to stem cell research would be removed or greatly reduced."
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research and development with Western management, StemCells Inc. (Nasdaq:STEM), which recently announced success in enabling once paralyzed mice to walk again, Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq:GERN).
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. An editor of SmallCap Sentinel currently holds a position of 1,100 shares of STEM. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.